Protalix BioTherapeutics, Inc.

PLX

Healthcare Biotechnology

Protalix BioTherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, down 1.23% from fiscal 2024.

Revenue
+27.1%
EPS
+2,281.0%
Free cash flow
−94.1%

Quarter to June 2026, against a year earlier

2.54 0.03 +1.20%
Market cap
$204.7M
P/E
10.6×
Fwd P/E
10.6×
Dividend yield
—
F-score
3/9
ROIC
48.5%
Net debt / EBITDA
7.7×
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
31.23% 27.27% (14.44%) 12.64%

+8 more TTM periods

Piotroski F-Score
7 7 3 6
ROA
20.07% 17.40% (8.48%) 7.50%
ROIC
48.48% 80.14% (19.92%) 16.91%
Return on Tangible Assets
28.58% 23.91% (14.66%) 10.95%
Average Days of Receivables
74.72 14.04 61.17 85.14
Free Cash Flow per Share
0.10 0.16 (0.17) (0.15)
Free Cash Flow
7.67 13.00 (13.63) (11.69)
Other line items

Show all line items

Columns are period end dates